{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:51:41Z","timestamp":1785520301703,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00259-021-05571-1","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T06:41:59Z","timestamp":1634280119000},"page":"1127-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9483","authenticated-orcid":false,"given":"Yasuyuki","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ichise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Suhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"5571_CR1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/bjp.2008.147","volume":"154","author":"TA Esbenshade","year":"2008","unstructured":"Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Brit J Pharmacol. 2008;154:1166\u201381.","journal-title":"Brit J Pharmacol"},{"key":"5571_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pharmthera.2019.04.007","volume":"200","author":"N Ghamari","year":"2019","unstructured":"Ghamari N, Zarei O, Arias-Monta\u00f1o J-A, Reiner D, Dastmalchi S, Stark H, et al. Histamine H3 receptor antagonists\/inverse agonists: where do they go? Pharmacol Therapeut. 2019;200:69\u201384.","journal-title":"Pharmacol Therapeut"},{"key":"5571_CR3","doi-asserted-by":"crossref","unstructured":"Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, et al. Long-term use of pitolisant to treat patients with narcolepsy: harmony III study. Sleep. 2019;42.","DOI":"10.1093\/sleep\/zsz174"},{"issue":"43","key":"5571_CR4","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s00259-016-3476-4","volume":"I","author":"A Takano","year":"2016","unstructured":"Takano A, Varrone A, Guly\u00e1s B, Salvadori P, Gee A, Windhorst A, et al. Guidelines to PET measurements of the target occupancy in the brain for drug development. Eur J Nucl Med Mol. 2016;I(43):2255\u201362.","journal-title":"Eur J Nucl Med Mol"},{"key":"5571_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1017\/S1461145712001411","volume":"16","author":"A Jucaite","year":"2012","unstructured":"Jucaite A, Takano A, Bostr\u00f6m E, Jostell K-G, Stenkrona P, Halldin C, et al. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. Int J Neuropsychoph. 2012;16:1231\u20139.","journal-title":"Int J Neuropsychoph"},{"key":"5571_CR6","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1111\/bph.15067","volume":"177","author":"P Rusjan","year":"2020","unstructured":"Rusjan P, Sabioni P, Ciano PD, Mansouri E, Boileau I, Laveill\u00e9 A, et al. Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET. Brit J Pharmacol. 2020;177:3464\u201372.","journal-title":"Brit J Pharmacol"},{"key":"5571_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF02243994","volume":"100","author":"DB Campbell","year":"1990","unstructured":"Campbell DB. The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology. 1990;100:433\u201350.","journal-title":"Psychopharmacology"},{"key":"5571_CR8","doi-asserted-by":"crossref","unstructured":"Hino N, Marumo T, Kotani M, Shimazaki T, Kaku-Fukumoto A, Hikichi H, et al. A novel potent and selective histamine H3 receptor antagonist enerisant: in vitro profiles, in vivo receptor occupancy, wake-promoting and pro-cognitive effects in rodents. J Pharmacol Exp Ther. 2020;375:JPET-AR-2020\u2013000185.","DOI":"10.1124\/jpet.120.000185"},{"key":"5571_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13550-016-0170-2","volume":"6","author":"K Koga","year":"2016","unstructured":"Koga K, Maeda J, Tokunaga M, Hanyu M, Kawamura K, Ohmichi M, et al. Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors. Ejnmmi Res. 2016;6:11.","journal-title":"Ejnmmi Res"},{"key":"5571_CR10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00259-016-3332-6","volume":"43","author":"Y Kimura","year":"2016","unstructured":"Kimura Y, Seki C, Ikoma Y, Ichise M, Kawamura K, Takahata K, et al. [11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain. Eur J Nucl Med Mol I. 2016;43:1653\u201363.","journal-title":"Eur J Nucl Med Mol I"},{"key":"5571_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.nucmedbio.2016.08.004","volume":"43","author":"M Hanyu","year":"2016","unstructured":"Hanyu M, Kawamura K, Takei M, Furutsuka K, Shiomi S, Fujishiro T, et al. Radiosynthesis and quality control of [11C]TASP457 as a clinically useful PET ligand for imaging of histamine H3 receptors in human brain. Nucl Med Biol. 2016;43:679\u201384.","journal-title":"Nucl Med Biol"},{"key":"5571_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuroimage.2005.02.018","volume":"26","author":"J Ashburner","year":"2005","unstructured":"Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839\u201351.","journal-title":"Neuroimage"},{"key":"5571_CR13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metabolism. 2007;27:1533\u20139.","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"5571_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.WCB.0000038000.34930.4E","volume":"22","author":"M Ichise","year":"2002","unstructured":"Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metabolism. 2002;22:1271\u201381.","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"5571_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/jcbfm.2009.190","volume":"30","author":"VJ Cunningham","year":"2010","unstructured":"Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metabolism. 2010;30:46\u201350.","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"5571_CR16","first-page":"4","volume":"40","author":"HILL Av","year":"1910","unstructured":"Av HILL. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (Lond). 1910;40:4\u20137.","journal-title":"J Physiol (Lond)"},{"key":"5571_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","volume":"6","author":"NHG Holford","year":"1981","unstructured":"Holford NHG, Sheiner LB. Understanding the dose-effect relationship. Clin Pharmacokinet. 1981;6:429\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"5571_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE T Automat Contr. 1974;19:716\u201323.","journal-title":"IEEE T Automat Contr"},{"key":"5571_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2967\/jnumed.113.122515","volume":"55","author":"KJV Laere","year":"2014","unstructured":"Laere KJV, Sanabria-Boh\u00f3rquez SM, Mozley DP, Burns DH, Hamill TG, Hecken AV, et al. 11C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists. J Nucl Med. 2014;55:65\u201372.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T10:06:47Z","timestamp":1647252407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5571"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05571-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by SOUSEIKAI Hakata Clinic Institutional Review Board and the Radiation Drug Safety Committee and the Institutional Review Board of the National Institute of Radiological Sciences, Japan, and was conducted in compliance with the ethical principles set forth in the Declaration of Helsinki, the standards stipulated in Article 14, Paragraph 3, and Article 80\u20132 of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics, and Good Clinical Practice (MHW Ordinance No. 28 dated March 27, 1997).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects gave written informed consent prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from all participants regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Taisho Pharmaceutical Co., Ltd., MH, and TSu hold a patent for [<sup>11<\/sup>C]TASP457 and related chemicals as histamine H<sub>3<\/sub> ligands (Japan patent JP2014047209A). TSh and IN are employees of Taisho Pharmaceutical Co., Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}